Risk Factors and Multiple Interaction Effects for Hyperammonemia in Patients Receiving Valproic Acid
Fundamental & Clinical Pharmacology · 2025
DOI: 10.1111/fcp.70030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, 2025. Verfasst von Chien-Chou Su und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Innovation and Research Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Hauptthemen laut MEDLINE: Valproic Acid, Hyperammonemia, Anticonvulsants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
Background
Valproic acid (VPA) use is associated with an increased risk of hyperammonemia (HA); however, the specific interactions between HA risk factors in VPA‐treated patients remain unclear.
Objectives
This study aimed to identify and assess the effects of multiple interactions between different risk factors affecting HA to improve clinical risk stratification in patients undergoing VPA therapy.
Methods
We conducted a retrospective cohort study by reviewing the medical records of patients treated with VPA at a single center from January 2019 to December 2021. The SHapley Additive exPlanations (SHAP) method was used to interpret model predictions, revealing the relative importance and interactions of factors affecting HA risk. SHAP interaction scores were used to assess the effects of multiple interactions between features, providing a comprehensive analysis of how risk factors interact.
Results
This study identified the Top 15 predictors of HA, ranked by importance: patient age, VPA blood concentration, VPA dose, epilepsy, VPA treatment duration, levetiracetam use, hypertension, mental disorders, and number of medications. Notable multiple interaction effects were observed, particularly between age and factors including VPA concentration, epilepsy, and treatment duration. Younger patients and those with elevated VPA concentrations were at increased risk of developing HA, especially when epilepsy or polypharmacy were present.
Conclusions
This study highlights several critical factors potentially influencing HA development in VPA‐treated patients, particularly younger patients, those with epilepsy, or those undergoing polypharmacy. However, as a single‐center retrospective study, these findings necessitate further validation through additional research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Innovation and Research Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Pharmacy, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
- Division of Neurology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
- Department of Pharmacy, School of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Nursing, Shu-Zen Junior College of Medicine and Management, Kaohsiung, Taiwan.
ORCID-Profile: Yi-Chia Su
Zitieren
APA
Su, C. C., Huang, T. K., Shih, C. S., & Su, Y. C. (2025). Risk Factors and Multiple Interaction Effects for Hyperammonemia in Patients Receiving Valproic Acid. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.70030
Vancouver
Su CC, Huang TK, Shih CS, Su YC. Risk Factors and Multiple Interaction Effects for Hyperammonemia in Patients Receiving Valproic Acid. Fundamental & Clinical Pharmacology. 2025. doi:10.1111/fcp.70030
BibTeX
@article{Su2025,
author = {Su, Chien-Chou and Huang, Tsai-Kuei and Shih, Ching-Sen and Su, Yi-Chia},
title = {Risk Factors and Multiple Interaction Effects for Hyperammonemia in Patients Receiving Valproic Acid},
journal = {Fundamental & Clinical Pharmacology},
year = {2025},
doi = {10.1111/fcp.70030}
}
EUVIMED